This course has expired. View available courses.
Infectious Disease
Eliminating Hepatitis C by 2030: what’s stigma got to do with it?
Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver. In Australia, over 170,000 people were estimated to have chronic HCV infection at the start of 2017 and 130,000 were still living with HCV at the end of 2018. The introduction of direct-acting antiviral (DAA) therapies, which can cure HCV in the majority of patients, represents a major advance and all Australians living with HCV should now be considered for DAA therapy. However, stigma represents a key barrier to diagnosis and treatment. As a result, Australia’s Fifth National Hepatitis C Strategy 2018–2022 has identified stigma and discrimination as one of five key priority areas for action.
This program is supported by an independent educational grant provided by Gilead sciences.
DURATION
1.5 hrs
PROFESSION
Physician
# OF CREDITS
3
ACCREDITATION
RACGP CPD Program
EXPIRY DATE
2022-12-31
Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver. In Australia, over 170,000 people were estimated to have chronic HCV infection at the start of 2017 and 130,000 were still living with HCV at the end of 2018. The introduction of direct-acting antiviral (DAA) therapies, which can cure HCV in the majority of patients, represents a major advance and all Australians living with HCV should now be considered for DAA therapy. However, stigma represents a key barrier to diagnosis and treatment. As a result, Australia’s Fifth National Hepatitis C Strategy 2018–2022 has identified stigma and discrimination as one of five key priority areas for action.
This program is supported by an independent educational grant provided by Gilead sciences.
Faculty
Prof Carla Treloar, Director of the Centre for Social Research in Health and the Social Policy Research Centre, UNSW
Dr Anne Balcomb, GP, Orange
Dr David Baker, GP, Sydney
Learning objectives
On completion of this program, participants will be better able to:
- Recognise the different ways in which stigma related to hepatitis C virus (HCV) infection can present in the primary care setting
- Describe the ways in which stigma can have a negative impact on outcomes for patients with HCV infection
- Understand the ways in which addressing stigma in primary care can help achieve the goal of eliminating HCV by 2030
- Confidently apply effective communication techniques and tools to overcome stigma and optimise outcomes for patient with HCV infection
Accreditation
This Active Learning Module has been approved by RACGP CPD Program for 3 CPD points.
Activity no. 226172
Members are able to claim CPD activity points for 3 points through ‘Quick log’ on their RACGP CPD Dashboard.
#
of credits: 3
Duration: 1.5 hrs
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1.5 hrs
Duration
Physician
Profession
3
# of credits
Learning Objectives
On completion of this program, participants will be better able to:
- Recognise the different ways in which stigma related to hepatitis C virus (HCV) infection can present in the primary care setting
- Describe the ways in which stigma can have a negative impact on outcomes for patients with HCV infection
- Understand the ways in which addressing stigma in primary care can help achieve the goal of eliminating HCV by 2030
- Confidently apply effective communication techniques and tools to overcome stigma and optimise outcomes for patient with HCV infection
RACGP CPD Program
ACCREDITATION
Infectious Disease
Learning Category
Hepatitis C
Topic
0
Price
2022-12-31
Expiry Date
AUS
Region/Language
Course Description
Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver. In Australia, over 170,000 people were estimated to have chronic HCV infection at the start of 2017 and 130,000 were still living with HCV at the end of 2018. The introduction of direct-acting antiviral (DAA) therapies, which can cure HCV in the majority of patients, represents a major advance and all Australians living with HCV should now be considered for DAA therapy. However, stigma represents a key barrier to diagnosis and treatment. As a result, Australia’s Fifth National Hepatitis C Strategy 2018–2022 has identified stigma and discrimination as one of five key priority areas for action.
This program is supported by an independent educational grant provided by Gilead sciences.
Faculty
Prof Carla Treloar, Director of the Centre for Social Research in Health and the Social Policy Research Centre, UNSW
Dr Anne Balcomb, GP, Orange
Dr David Baker, GP, Sydney
Accreditation
This Active Learning Module has been approved by RACGP CPD Program for 3 CPD points.
Activity no. 226172
Members are able to claim CPD activity points for 3 points through ‘Quick log’ on their RACGP CPD Dashboard.
1.5 hrs
Duration
0
Price
3
# of credits
